# Wave Life Sciences

Type: Company (WVE)

Source: GetYourBrief — https://getyourbrief.com/entity/wave-life-sciences
Canonical HTML page: https://getyourbrief.com/entity/wave-life-sciences

## Timeline

- **2026-02-26**: FY 2025 Earnings — Wave and Collegium release full-year financial results and 2026 guidance.
- **2026**: Anticipated Filing — Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
- **2025-Q4**: RNA Editing Milestone — WVE-006 demonstrates successful RNA editing in AATD patients.
- **2025-Q2**: DMD Breakthrough — Wave reports industry-leading dystrophin expression for WVE-N531.

## Recent coverage (5 stories, network-wide)

### Wave's WVE-007 Silences Activin E by 88%, Sustained for 7.5 Months in Phase I
2026-08-04 04:01:27 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Full story: https://getbiobrief.com/story/wave-007-88-percent-activin-e-silencing

### Wave's Obesity siRNA Shows 16.5% Visceral Fat Improvement, Targeting 175M Patients
2026-08-04 03:59:45 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Full story: https://gethealthbrief.com/story/wave-obesity-siRNA-16-5-vmr

### Pharma Earnings: Wave Life Sciences and Collegium Report 2025 Results
2026-02-26 14:29:40 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Full story: https://getfinancebrief.com/story/wave-life-sciences-collegium-2025-earnings-analysis

### Wave Life Sciences and Collegium FY2025 Results Signal RNA and Pain Pivot
2026-02-26 14:28:36 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
Full story: https://getbiobrief.com/story/wave-life-sciences-collegium-fy2025-earnings-analysis

### Wave Life Sciences and Collegium Report 2025 Results Amid RNA Breakthroughs
2026-02-26 14:24:42 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Full story: https://gethealthbrief.com/story/wave-life-sciences-collegium-2025-financials-rna-editing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.